|
Non-Hodgkins Lymphoma (NHL) News Items
Cancer therapy wipes out most of man's tumors
Three months ago, William Hesse had a radioactive liquid infused into his bloodstream in the hope of turning back a recurrence of cancer. It was a new approach to treatment that combines an antibody with a radioactive isotope to deliver a killing dose of radiation directly to malignant cells.
BIOVAXID Cancer Immunotherapy Vaccine For Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma (NHL) is a group of cancers that originate in the lymphatic system. It is the fifth most common cancer in the United States with an estimated 65,000 new cases diagnosed each year. The cause of non-Hodgkin's lymphoma is unknown however it is not considered hereditary.
Study of PDX in Patients with Cutaneous T-Cell Lymphoma
The cutaneous T-cells lymphomas are comprised of a number of non-Hodgkins T-cell lymphomas, including mycosis fungoides and Sezary syndrome, which have their primary manifestations in the skin. According to the Lymphoma Research Foundation, CTCL comprises about 2% to 3% of the estimated 63,000 new cases of non-Hodgkin's lymphoma diagnosed annually.
Cancer fight is more than chemo
Bill Carper, a 59-year-old Everett patient being treated for a recurrence of non-Hodgkins lymphoma, is one of the first patients to receive acupuncture treatments at the cancer center.
MabThera maintenance therapy dramatically improves survival for patients with lymphoma
Two years of maintenance therapy with MabThera (rituximab) dramatically improves the chances of survival for patients suffering from one of the most frequent forms of lymphoma, indolent non-Hodgkin’s Lymphoma (NHL). The trial showed that the risk of death is halved for patients who receive MabThera maintenance therapy, compared to those who receive no maintenance treatment, irrespective of their initial therapy.
Breakthrough MabThera data now shows patients with indolent Non-Hodgkin’s Lymphoma can live longer
For the first time, clear data shows that treating Indolent Non-Hodgkin’s Lymphoma (NHL) with MabThera in combination with chemotherapy prolongs patient survival. The study, presented at the annual meeting of the American Society of Haematology (ASH), compared MabThera in combination with chemotherapy (R-MCP1) vs. chemotherapy alone (MCP2), as first-line treatment for patients suffering from indolent NHL.
MabThera (Rituxan) for non-Hodgkin's lymphoma (NHL)
MabThera is indicated as a single-agent treatment for relapsed or refractory indolent NHL, and received European approval in March 2002 for the treatment of aggressive NHL in combination with CHOP chemotherapy. MabThera is known as Rituxan in the United States, Japan and Canada.
'Guns & Hoses' hockey benefit to help boy with Burkitt's lymphoma cancer
Burkitt's lymphoma is a rare form of non-Hodgkins lymphoma, with only 184 cases reported last year in the United States. "About 65 percent of the cases respond very well to chemotherapy, which is what happened with Cole," his mother said.
Adding Radioimmunotherapy To Chemotherapy Reduces Relapse Risk In Mantle Cell Leukemia Patients
A new cancer treatment that combines the power of radioactive monoclonal antibodies with high-dose chemotherapy and the patient's own blood stem cells is showing encouraging results in early studies, according to researchers at City of Hope Cancer Center. Results of the clinical trial, conducted on patients with mantle cell lymphoma (MCL), a type of non-Hodgkins lymphoma, were announced today at the American Society of Hematology's 47th annual meeting.
Death rate from cancers still dropping
The institute, a part of the National Institutes of Health, said there have been continuing increases in the incidence of cancers of the breast in women and of prostate and testicles in men, as well as leukemia, non-Hodgkins lymphoma, myeloma, melanoma of skin, and cancers of the thyroid, kidney, and esophagus.
Everyday products expose us to toxic chemicals
Breast cancer incidence rates have climbed 90 percent since 1950. Non-Hodgkins lymphoma, a cancer tied to a weakened immune system, has seen a 250 percent jump in incidence rates.
Pregnant television news anchor fights cancer
She later learned she had the anaplastic large-cell form of non-Hodgkins lymphoma, which responds rapidly to chemotherapy and is considered curable. A specialist at the Dana-Farber Cancer Institute in Boston gave her a 70 percent chance of survival. The next day Kingsfield started chemotherapy, and within days, the swelling on her neck was all but gone.
Biologist offers new hope for Valley sugar as pharmaceutical
But Mirkov said sugar cane's simple genetic makeup compared to other crops would make the splicing with human genes easier and less expensive. By comparison, he cited his wife Kaye's successful treatment of non-Hodgkins lymphoma with a protein-based drug called Rituxan, which at the time cost $8,000 for one treatment. His wife needed eight.
Zevalin (Rituxin) Scan and Treatment
In the Cancer Center treatment room, the patient was infused with Rituxin over a four hour period. Once the infusion of Rituxin was complete, the Nuclear Medicine Technologist infused 111In-Zevalin over a 10 minute period.
Potato hepatitis vaccine a success
Other researchers have tinkered with the genetic makeup of tomatoes, tobacco, corn and other crops to produce promising compounds for the treatment of cystic fibrosis and non-Hodgkins lymphoma, as well as plant-based growth hormones, contraceptives and blood thinners.
Non-Hodgkin's Lymphoma Cancer Survitor: Embracing Life
Dr. Paul Michael, an oncologist at Comprehensive Cancer Centers of Nevada, saw Marino shortly after the initial diagnosis of non-Hodgkins lymphoma was made. Even though the tumor was large the initial prognosis for her was good. For non-Hodgkins lymphoma, generally speaking, you have a reasonably good prognosis if you can catch it early enough and the cancer hasn't spread
Non-Hodgkins Lymphoma Survivors Aid Others
Karen McClanahan owes much of her quality of life to advancements in cancer treatments. The 51-year-old, a mother of two and grandmother of three, was diagnosed with non-Hodgkins lymphoma six years ago. It’s incurable, but treatments are available until they find a cure
Added Rituxan® Improves Initial Treatment of Follicular Lymphoma with CVP
The monoclonal antibody Rituxan® is widely used to treat patients with B-cell non-Hodgkin’s lymphomas (NHL) who express CD20. The results to date suggest that Rituxan® is effective palliative therapy for patients who have failed initial chemotherapy.
Xcyte Therapies, Inc. Presents Results of Two Clinical Trials of Xcellerated T Cells
Dr. Ron Berenson, President and Chief Executive Officer of Xcyte Therapies, presented preliminary results from a Phase II study of Xcellerated T Cells in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL).
Sun Exposure Does Not Increase Risk of Developing Lymphoma
Researchers from Sweden and Denmark have reported that ultraviolet (UV) exposure does not increase the incidence of malignant lymphomas, but instead is associated with a lower incidence of non-Hodgkin’s lymphoma (NHL).
Gene Expression Predicts Survival in Follicular Lymphoma
Follicular lymphoma is a type of non-Hodgkin’s lymphoma (NHL), which is a form of cancer that begins in the cells of the lymph system. The lymph system includes the spleen, thymus, tonsils, bone marrow, lymph nodes and circulating immune cells
Use Of Velcade Widening As Various Trials March On
Non-Hodgkin's lymphoma is another targeted disease for Velcade, specifically follicular/marginal zone lymphoma and mantle-cell lymphoma, known as "indolent" and "aggressive" NHL, respectively. A Phase II study in relapsed/refractory mantle-cell lymphoma is ongoing
Parent Cancer group formed to investigate cases of lymphoma
Seven years ago, people began to notice a disturbing number of lymphoma cases among recent graduates of East Hampton High School. Eight cases of Hodgkins and non-Hodgkins lymphoma were eventually found, a startlingly high number for a school district with fewer than 2,000 students.
Gary is all smiles as he finds bone marrow match
LAST Monday Gary Mitchell was in a state of depression. By the next day he was popping champagne corks. Gary, an Ashtead resident, was diagnosed with non-Hodgkins lymphoma and chronic lymphatic leukaemia in April this year. He has been crossing his fingers that a suitable bone marrow donor be found which would give him the best chance of survival.
Genitope Corporation Provides Update on Progress of Lead Product Candidate
Genitope Corporation announced that its independent Data Safety Monitoring Board (DSMB) met on November 15, 2004 to review data from Genitope Corporation's pivotal Phase 3 clinical trial to evaluate the safety and efficacy of the company's lead product candidate, MyVax(R) Personalized Immunotherapy, in patients with previously untreated follicular non-Hodgkin's lymphoma (f-NHL).
NON-HODGKIN'S LYMPHOMA SEMINAR TODAY
Dr. Luis E. Fayad, assistant professor of medicine, will speak at a "Meet The Expert on Non-Hodgkin's Lymphoma" meeting, sponsored by The Leukemia and Lymphoma Society of Northeast Texas. The meeting is free.
Family of cancer victim promotes drive for stem-cell donations
Gregg Schaub was diagnosed with non-Hodgkins lymphoma in 2001. Two years later, at age 34 and after enduring chemotherapy for his cancer, he died while waiting for a stem-cell transplant - a last-chance effort to save his life.
|
